<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Introduction: <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Malignancy</z:e> in LUC (long-standing <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>) presumably evolves through a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-adeno-<z:mp ids='MP_0002038'>carcinoma</z:mp> sequence in which a multitude of yet not fully understood factors takes part </plain></SENT>
<SENT sid="1" pm="."><plain>Aim: To assess <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) associated <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and to distinguish regenerative changes from premalignant ones using immunohistochemical (IHC) markers </plain></SENT>
<SENT sid="2" pm="."><plain>Materials and Methods: We studied 80 LUC biopsy specimens: 20 high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD), 20 low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (LGD), 20 indefinite for <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 20 regenerative atypia </plain></SENT>
<SENT sid="3" pm="."><plain>We used anti-COX-2 and Ki-67 antisera (Dako, Carpinteria, USA) to perform immunohistochemical staining by the labeled Streptavidin-<z:chebi fb="1" ids="15956">Biotin</z:chebi> method, and then assessed and graded staining intensity and distribution using previously described scoring systems </plain></SENT>
<SENT sid="4" pm="."><plain>Statistical analysis was made using chi-square test and SPSS application </plain></SENT>
<SENT sid="5" pm="."><plain>A p-value &lt;0.05 was considered significant </plain></SENT>
<SENT sid="6" pm="."><plain>Results: In LGD, most of the cases had middle and top Ki-67 localization of the staining </plain></SENT>
<SENT sid="7" pm="."><plain>For HGD, we found to be characteristic the top and surface staining of the crypts and no case of basal immunostaining </plain></SENT>
<SENT sid="8" pm="."><plain>COX-2 immunostaining was positive (total score &gt;=3) in 72.5% of <z:hpo ids='HP_0000001'>all</z:hpo> the UC cases studied </plain></SENT>
<SENT sid="9" pm="."><plain>In non-dysplastic lesions (regenerative atypia), COX-2 expression was negative and as the pathologic process progressed towards <z:mpath ids='MPATH_589'>dysplasia</z:mpath>รท<z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e>, COX-2 expression became positive with a progressive increase of the total score </plain></SENT>
<SENT sid="10" pm="."><plain>Conclusions: A combination of enhanced colonoscopic surveillance and IHC markers those are more sensitive for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> might be the optimal way to manage the increased <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) risk in LUC patients </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies to find additional prognostic parameters will provide valuable insights into the behavior of LUC </plain></SENT>
</text></document>